The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors

European Journal of Pharmacology

Volumn 364, Issue 1, 1999, Pages 33-41

  Andringa, Gerda ^a,b   Drukarch, Benjamin ^a   Leysen, Josée E ^a,c   Cools, Alexander R ^b   Stoof, Johannes C ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Adenylate cyclase; Benzazepine; Dopamine D1 receptor agonist; Parkinson's disease; SKF 83959

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLBENZYL) 1H BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; ALPHA 2 ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; CATECHOLAMINE RECEPTOR; CYANOPINDOLOL I 125; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; NISOXETINE; PHENTOLAMINE; PRAZOSIN; RAUWOLSCINE; RECEPTOR SUBTYPE; SPIPERONE; SULPIRIDE; UNCLASSIFIED DRUG; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ACETYLCHOLINE; ADRENERGIC RECEPTOR; CARRIER PROTEIN; COTRANSPORTER; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; NORADRENALIN; NORADRENALIN TRANSPORTER; SK&F 83959; SLC6A2 PROTEIN, HUMAN; SLC6A2 PROTEIN, RAT;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG RECEPTOR BINDING; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MONKEY; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; ANIMAL; BIOSYNTHESIS; BRAIN; DRUG EFFECT; ELECTROSTIMULATION; GLIA; MACACA; MALE; METABOLISM; SPECIES DIFFERENCE; WISTAR RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ACETYLCHOLINE; ANIMALS; BRAIN; CARRIER PROTEINS; CELLS, CULTURED; CYCLIC AMP; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTRIC STIMULATION; HUMANS; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEUROGLIA; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; SPECIES SPECIFICITY; SYMPORTERS;

EID: 0032590059     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00825-5     Document Type: Article

References (46)

1. Alvord E.C. Jr., Forno L.S., Kusske J.A., Kaufman R.J., Rhodes J.S., Goetowski C.R. The pathology of Parkinsonism: a comparison of degeneration in the cerebral cortex and the brain stem. Adv. Neurol. 5:1974;175.
2. Andén N.E., Strombom U., Svensson T.H. Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity. Psychopharmacologia. 29(4):1973;289.
3. 1 receptor efficacy. Eur. J. Pharmacol. Mol. Pharamacol. Sect. 188(6):1990;335.
4. Andringa G., Vermeulen R.J., Drukarch B., Stoof J.C., Cools A.R. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease. Adv. Pharmacol. 42:1998;792.
5. 1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur. J. Pharmacol. 213(2):1992;259.
6. 1 receptor mediated stimulation of rat striatal adenylate cyclase activity following irreversible modification by N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): evidence for spare receptors. Neurosci. Lett. 69:1986;290.
7. Colpaert F.C., Degryse A.D., Van Craenendonck H.V. Effects of an alpha 2 antagonist in a 20-year-old java monkey with MPTP-induced parkinsonian signs. Brain Res. Bull. 26(4):1991;627.
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22(23):1973;3099.
9. 1 receptor. Eur. J. Pharmacol. 119(2):1991;209.
10. 1-like' dopamine receptors not linked to adenylyl cyclase. Br. J. Pharmacol. 116(3):1995;2120.
11. 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by D-amphetamine and apomorphine in the rat. Psychopharmacology. 96:1988;521.
12. Dolphin A.C., Jenner P., Marsden C.D. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacol. Biochem. Behav. 4(6):1977;661.
13. Domino E.F. Talipexole and pramipexole combinations with chloro APB (SKF 82958) in MPTP induced hemiparkinsonian monkeys. Eur. J. Pharmacol. 325(2-3):1997;137.
14. 1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur. J. Pharmacol. 234(1):1993;135.
15. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human striatum: topographic distribution in normal and in Parkinson's disease and their role in akinesia, rigidity and tremor. J. Neurol. Sci. 14:1971;427-455.
16. 1 receptor agonists with varying efficacies in the MPTP-treated marmoset. Psychopharmacology. 117:1995;275.
17. 1 dopamine antagonists in the primate. Psychopharmacology. 117:1995;403.
18. 1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat-relationship to circling. Behav. Biochem. Pharmacol. 49(9):1995;1185.
19. 1 receptors in drug-naive MPTP monkeys. Brain Res. 719(1-2):1996;129.
20. 1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 246:1993;39.
21. 1 receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol. Biochem. Behav. 51(4):1995;617.
22. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93.
23. 1 receptor agonist with anti-parkinsonian activity in marmosets. Eur. J. Pharmacol. 229:1990;203.
24. Langtry H.D., Clissold S.P. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 39:1990;491.
25. 3H ]alniditan Mol. Pharmacol. 50:1996;1567.
26. 2 agonists and antagonists. Brain Res. 562:1991;216.
27. Mishra R.K., Marshal A.M., Varmuza S.L. Supersensitivity in the rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine and cyclic AMP changes. Brain Res. 200:1980;47.
28. 1 dopamine receptor: behavioural and neurochemical comparison of CY 208-243 with SK&F 101384 and SK&F 103243. Pharmacol. Biochem. Behav. 35(1):1990;105.
29. Oestreicher E.G., Pinto G.F. A microcomputer program for fitting enzyme inhibition rate equations. Comput. Biol. Med. 17:1987;53.
30. Parker J.D., Debono A.G., Marsden C.D. Bromocriptine in parkinsonism: long-term treatment, dose response, and comparison with levodopa. J. Neurol. Neurosurg. Psychiatry. 39:1976;1101.
31. Pichler L., Pifl C. Locomotor behaviour of selective dopamine agonists in mice: is endogenous dopamine the only catecholamine involved? J. Pharm. Pharmacol. 41:1989;690.
32. 1 receptor agonist SKF 38939, to stimulate adenelyl cyclase activity in primate than in rodent striatum. Eur. J. Pharmacol. 202(2):1991;273.
33. Pifl C., Reiter H., Hornykiewics O. Functional sensitisation of striatal dopamine receptors in the 6-hydroxydopamine treated rat. Brain Res. 572:1992;87.
34. 1 receptor-dependent cyclic AMP production in striatal tissue. Eur. J. Pharmacol. 331(1):1997;23.
35. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared to new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57.
36. 2 agonists. J. Neural. Transm. Parkinson's Disease Sect. 7:1994;133.
37. 2 dopamine receptors in efflux of cyclic AMP from rat striatum. Nature. 294:1981;366.
38. Stoof J.C., Kebabian J.W. AMP and K+-stimulated release of acetylcholine from rat neostriatum. Brain Res. 250(2):1982;263.
39. Stoof J.C., Kebabian J.W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 35:1984;2281.
40. Undie A.S., Friedman E. Dopamine stimulates phosphoinositide metabolism in rat brain. Neurosci. Res. Commun. 6:1990;69.
41. Undie A.S., Friedman E. Selective dopaminergic mechanism of dopamine and SKF 38939 stimulation of inositol phosphate formation in rat brain. Eur. J. Pharmacol. 226:1992;297-302.
42. 1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62(5):1994;2045.
43. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485.
44. 1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur. J. Pharmacol. 269:1994;121.
45. 1 receptors: efficacy of full (dihydrexine) partial (SKF 38393) agonists in primates vs. rodents. Eur. J. Pharmacol. 242:1993;165.
46. Wemer J., van der Lugt J.C., de Langen C.D., Mulder A.H. On the capacity of presynaptic alpha receptors to modulate norepinephrine release from slices of rat neocortex and the affinity of some agonists and antagonists for these receptors. J. Pharmacol. Exp. Ther. 211:1979;445.